NVO Stock Price Today (October 2026) — Novo Nordisk A/S Analysis & Key Metrics 2026-10-20
Novo Nordisk A/S (NVO) is trading at $39.35, up 2.42% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $45.71 (16.2% upside).
- Volatility is low (18.04% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: steady revenue (2.10% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
NVO Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Novo Nordisk A/S - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $268.80B
P/E Ratio
Forward P/E: 13.29
Revenue Growth
Year over Year
Analyst Target
+16.2% upside potential
Key Investor Questions About NVO
What investors need to know before buying
Based on current market data, NVO presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 52.21)
- Fundamentals say: Mixed signals (nuanced financial profile)
NVO's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NVO investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $140.13B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, NVO stock traded between $35.12 and $64.16 and currently trades near the low end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 18.04% annualized volatility and β=1.03, the stock exhibits moderate correlation to market moves—making NVO suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Moderate ownership metrics suggest a balanced supply-demand dynamic.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
OpenAI acquires startup Orchestra Bio to beef up its biotech business
Hims & Hers Stock Jumps on Major European Expansion
OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports
Prothena's Partnership Strategy: Growth Driver or Limitation?
If Eli Lilly Grows At 10% a Year, Here’s What $1,000 Becomes By 2030
Can Viking Therapeutics Carve Out a Place in the Obesity Market?
Latest TickZen Insights
All insights →No TickZen article on NVO yet. Our newest analysis:
Explore More Analysis for NVO
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 4, 2026
Frequently Asked Questions
Common investor questions about Novo Nordisk A/S
Novo Nordisk A/S (NVO) is currently trading at $39.35. The RSI (14-day) is at 52.2, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $45.71 implies 16.2% upside from current levels. Volatility is low at 18.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Novo Nordisk A/S (NVO): The trailing P/E ratio is 10.62, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 13.29. The PEG ratio is 3.14, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 5.58. Price-to-Sales is 0.44. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering NVO, the consensus price target is $45.71. This represents a 16.2% upside from the current price of $39.35. The range spans from a low target of $39.82 to a high target of $61.90, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Novo Nordisk A/S (NVO) pays a dividend with a current yield of approximately 4.57%. The annualized dividend rate is $11.70 per share. The payout ratio is 45.1%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Aug 17, 2026.
Key risks for Novo Nordisk A/S (NVO) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Novo Nordisk A/S's (NVO) current debt and financial health profile: Total debt stands at $140.13B. The debt-to-equity ratio is 0.63x, which is moderate and generally manageable for most companies. The current ratio is 0.87, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.64. The company holds $44.98B in cash and equivalents. Free cash flow is positive at $37.67B, providing a cushion for debt servicing and shareholder returns.